MXPA03001634A - Polipeptido tumoral cripto. - Google Patents
Polipeptido tumoral cripto.Info
- Publication number
- MXPA03001634A MXPA03001634A MXPA03001634A MXPA03001634A MXPA03001634A MX PA03001634 A MXPA03001634 A MX PA03001634A MX PA03001634 A MXPA03001634 A MX PA03001634A MX PA03001634 A MXPA03001634 A MX PA03001634A MX PA03001634 A MXPA03001634 A MX PA03001634A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- compositions
- colorectal
- colon
- diagnosis
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000001072 colon Anatomy 0.000 abstract 2
- 208000029742 colonic neoplasm Diseases 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 201000005202 lung cancer Diseases 0.000 abstract 2
- 208000020816 lung neoplasm Diseases 0.000 abstract 2
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A61K39/4611—
-
- A61K39/4644—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen composiciones y procedimientos para la terapia y el diagnostico del cancer, en particular, cancer de pulmon, de colon, colorrectal y de mama. Las composiciones ilustrativas comprenden uno o mas polipeptidos tumorales Cripto, porciones inmunogenas de los mismos, polinucleotidos que codifican tales polipeptidos, celulas presentadoras de antigenos que expresan tales polipeptidos y celulas T que son especificas para las celulas que expresan tales polipeptidos. Las composiciones descritas son utiles, por ejemplo, en el diagnostico, prevencion y/o tratamiento de enfermedades, en particular, de cancer de pulmon, de colon, colorrectal y de mama.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0020953.6A GB0020953D0 (en) | 2000-08-24 | 2000-08-24 | Vaccine |
| PCT/EP2001/009646 WO2002016413A2 (en) | 2000-08-24 | 2001-08-20 | Cripto tumour polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03001634A true MXPA03001634A (es) | 2004-09-10 |
Family
ID=9898284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03001634A MXPA03001634A (es) | 2000-08-24 | 2001-08-20 | Polipeptido tumoral cripto. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7439320B2 (es) |
| EP (1) | EP1311678A2 (es) |
| JP (1) | JP2004506441A (es) |
| KR (1) | KR20030045041A (es) |
| CN (1) | CN1471579A (es) |
| AR (1) | AR032173A1 (es) |
| AU (1) | AU2001295498A1 (es) |
| BR (1) | BR0113491A (es) |
| CA (1) | CA2420087A1 (es) |
| CZ (1) | CZ2003537A3 (es) |
| GB (1) | GB0020953D0 (es) |
| HU (1) | HUP0302824A2 (es) |
| IL (1) | IL154533A0 (es) |
| MX (1) | MXPA03001634A (es) |
| NO (1) | NO20030823L (es) |
| NZ (1) | NZ524344A (es) |
| PL (1) | PL363005A1 (es) |
| WO (1) | WO2002016413A2 (es) |
| ZA (1) | ZA200301436B (es) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR395801A0 (en) * | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| EP2316486A3 (en) | 2001-04-26 | 2011-09-07 | Biogen Idec MA Inc. | Cripto blocking antibodies and uses thereof |
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| EP1494693B1 (en) * | 2002-03-22 | 2010-12-08 | Biogen Idec MA Inc. | Cripto-specific antibodies |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
| CA2567520A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Maytansinoid-antibody conjugates |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
| KR20070100346A (ko) | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | 크립토 결합 분자 |
| US8527510B2 (en) | 2005-05-23 | 2013-09-03 | Monster Worldwide, Inc. | Intelligent job matching system and method |
| US8195657B1 (en) | 2006-01-09 | 2012-06-05 | Monster Worldwide, Inc. | Apparatuses, systems and methods for data entry correlation |
| US8600931B1 (en) | 2006-03-31 | 2013-12-03 | Monster Worldwide, Inc. | Apparatuses, methods and systems for automated online data submission |
| AU2007243181A1 (en) * | 2006-04-28 | 2007-11-08 | Biogen Idec Ma Inc. | Composition and methods for the detection of Cripto-3 |
| WO2008040759A1 (en) * | 2006-10-03 | 2008-04-10 | Pharmexa A/S | Method for down-regulation of cripto |
| US8645817B1 (en) | 2006-12-29 | 2014-02-04 | Monster Worldwide, Inc. | Apparatuses, methods and systems for enhanced posted listing generation and distribution management |
| US8244551B1 (en) | 2008-04-21 | 2012-08-14 | Monster Worldwide, Inc. | Apparatuses, methods and systems for advancement path candidate cloning |
| EP2475391B1 (en) | 2009-09-09 | 2018-09-12 | Centrose, LLC | Extracellular targeted drug conjugates |
| AU2011239507B2 (en) | 2010-04-15 | 2015-04-09 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CA3220104A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
| US8679767B2 (en) | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| AU2012322607B2 (en) | 2011-10-14 | 2017-02-16 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| BR112015008173A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolobenzodiazepina-anticorpo anti-psma |
| CN105102004B (zh) | 2012-10-12 | 2019-01-25 | Adc疗法责任有限公司 | 吡咯并苯并二氮杂卓-抗cd22抗体结合物 |
| EA035405B1 (ru) | 2012-10-12 | 2020-06-08 | Медимьюн Лимитед | Пирролбензодиазепины и их конъюгаты |
| JP6392764B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ | ピロロベンゾジアゼピン−抗体結合体 |
| JP6392763B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ | ピロロベンゾジアゼピン−抗体結合体 |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| BR112015014669B1 (pt) | 2012-12-21 | 2023-09-26 | Medimmune Limited | Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa |
| CA2904044C (en) | 2013-03-13 | 2020-03-31 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| TWI636792B (zh) | 2013-08-12 | 2018-10-01 | 建南德克公司 | １－（氯甲基）－２，３－二氫－１ｈ－苯并［ｅ］吲哚二聚體抗體－藥物結合物化合物及使用與治療方法 |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| SG11201604905WA (en) | 2013-12-16 | 2016-07-28 | Genentech Inc | Peptidomimetic compounds and antibody-drug conjugates thereof |
| CN105873614B (zh) | 2013-12-16 | 2020-10-30 | 基因泰克公司 | 肽模拟化合物及其抗体-药物缀合物 |
| CA2929565A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| US20170330153A1 (en) | 2014-05-13 | 2017-11-16 | Monster Worldwide, Inc. | Search Extraction Matching, Draw Attention-Fit Modality, Application Morphing, and Informed Apply Apparatuses, Methods and Systems |
| WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP6622293B2 (ja) | 2014-09-12 | 2019-12-18 | ジェネンテック， インコーポレイテッド | アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| KR20170052600A (ko) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | 시스테인 가공된 항체 및 콘주게이트 |
| WO2016044560A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| JP6752204B2 (ja) | 2014-12-03 | 2020-09-09 | ジェネンテック， インコーポレイテッド | 四級アミン化合物及びその抗体−薬物コンジュゲート |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| US10691773B2 (en) | 2015-12-30 | 2020-06-23 | General Electric Company | Cell processing techniques |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| MA55153A (fr) * | 2016-02-19 | 2021-09-29 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers |
| JP6943872B2 (ja) | 2016-03-25 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 多重全抗体及び抗体複合体化薬物定量化アッセイ |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
| US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
| WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
| EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| PT3544636T (pt) | 2017-02-08 | 2021-05-04 | Medimmune Ltd | Conjugados de anticorpos-pirrolobenzodiazepinas |
| LT3612537T (lt) | 2017-04-18 | 2022-10-10 | Medimmune Limited | Pirolobenzodiazepino konjugatai |
| JP7408396B2 (ja) | 2017-04-20 | 2024-01-05 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
| BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
| MY194477A (en) | 2017-08-18 | 2022-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| KR20200055065A (ko) | 2017-09-20 | 2020-05-20 | 주식회사 피에이치파마 | 타일란스타틴 유사체 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| CA3115110A1 (en) | 2018-10-24 | 2020-04-30 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| TW202432187A (zh) | 2022-12-23 | 2024-08-16 | 美商建南德克公司 | 小腦蛋白降解劑結合物及其用途 |
| WO2024220546A2 (en) | 2023-04-17 | 2024-10-24 | Peak Bio, Inc. | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256643A (en) * | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| US5264557A (en) * | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US5633147A (en) * | 1994-03-08 | 1997-05-27 | Human Genome Sciences, Inc. | Transforming growth factor αH1 |
| US6270777B1 (en) * | 1996-12-20 | 2001-08-07 | University Technologies International Inc. | Conserved metalloprotease epitopes |
| US5834399A (en) * | 1997-12-22 | 1998-11-10 | Eastman Kodak Company | Subbing layer for dye-donor element used in thermal dye transfer |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| US6387888B1 (en) * | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
| US6537552B1 (en) * | 1999-10-19 | 2003-03-25 | Iowa State University Research Foundation | Vaccine adjuvant |
| WO2001094629A2 (en) | 2000-06-05 | 2001-12-13 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
-
2000
- 2000-08-24 GB GBGB0020953.6A patent/GB0020953D0/en not_active Ceased
-
2001
- 2001-08-20 WO PCT/EP2001/009646 patent/WO2002016413A2/en not_active Application Discontinuation
- 2001-08-20 EP EP01976131A patent/EP1311678A2/en not_active Withdrawn
- 2001-08-20 AU AU2001295498A patent/AU2001295498A1/en not_active Abandoned
- 2001-08-20 PL PL01363005A patent/PL363005A1/xx unknown
- 2001-08-20 US US10/362,597 patent/US7439320B2/en not_active Expired - Fee Related
- 2001-08-20 CA CA002420087A patent/CA2420087A1/en not_active Abandoned
- 2001-08-20 CN CNA018177336A patent/CN1471579A/zh active Pending
- 2001-08-20 MX MXPA03001634A patent/MXPA03001634A/es not_active Application Discontinuation
- 2001-08-20 JP JP2002521508A patent/JP2004506441A/ja active Pending
- 2001-08-20 CZ CZ2003537A patent/CZ2003537A3/cs unknown
- 2001-08-20 IL IL15453301A patent/IL154533A0/xx unknown
- 2001-08-20 KR KR10-2003-7002701A patent/KR20030045041A/ko not_active Application Discontinuation
- 2001-08-20 BR BR0113491-4A patent/BR0113491A/pt not_active IP Right Cessation
- 2001-08-20 HU HU0302824A patent/HUP0302824A2/hu unknown
- 2001-08-20 NZ NZ524344A patent/NZ524344A/en unknown
- 2001-08-23 AR ARP010104025A patent/AR032173A1/es not_active Application Discontinuation
-
2003
- 2003-02-21 ZA ZA200301436A patent/ZA200301436B/xx unknown
- 2003-02-21 NO NO20030823A patent/NO20030823L/no not_active Application Discontinuation
- 2003-04-04 US US10/407,481 patent/US20040138112A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002016413A3 (en) | 2002-12-05 |
| HUP0302824A2 (hu) | 2005-05-30 |
| NZ524344A (en) | 2004-07-30 |
| WO2002016413A2 (en) | 2002-02-28 |
| CZ2003537A3 (cs) | 2003-09-17 |
| CN1471579A (zh) | 2004-01-28 |
| AR032173A1 (es) | 2003-10-29 |
| WO2002016413A8 (en) | 2003-02-06 |
| AU2001295498A1 (en) | 2002-03-04 |
| US20040138112A1 (en) | 2004-07-15 |
| EP1311678A2 (en) | 2003-05-21 |
| BR0113491A (pt) | 2003-06-24 |
| KR20030045041A (ko) | 2003-06-09 |
| ZA200301436B (en) | 2004-05-21 |
| JP2004506441A (ja) | 2004-03-04 |
| US20040054142A1 (en) | 2004-03-18 |
| NO20030823D0 (no) | 2003-02-21 |
| CA2420087A1 (en) | 2002-02-28 |
| PL363005A1 (en) | 2004-11-15 |
| GB0020953D0 (en) | 2000-10-11 |
| US7439320B2 (en) | 2008-10-21 |
| NO20030823L (no) | 2003-04-23 |
| IL154533A0 (en) | 2003-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03001634A (es) | Polipeptido tumoral cripto. | |
| WO2001072295A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2002074156A3 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| MXPA03001389A (es) | Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu. | |
| WO2001092581A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| WO2002060317A3 (en) | Compositions and methods for the therapy and diagnosis of pancreatic cancer | |
| WO2002004514A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2001051633A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| WO2001073032A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| WO2004052276A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| WO2002092001A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2002012328A3 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| WO2002074237A3 (en) | Compositions and methods for the therapy and diagnosis of kidney cancer | |
| WO2002078516A3 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
| WO2002058534A3 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| WO2003037267A8 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2001077168A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| MXPA02011563A (es) | Composicionesy metodos para la terapia y diagnostico de cancer de seno. | |
| WO2003013431A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
| WO2002012280A3 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| WO2002039885A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| WO2006031363A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2005051990A3 (en) | Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer | |
| WO2002000174A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2003086175A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |